Year: 2022
Type: review
Abstract: CONTEXT: Pediatric obesity is a serious health problem in the United States. While lifestyle modification therapy with dietary changes and increased physical activity are integral for the prevention and treatment of mild to moderate obesity in youth, only a modest effect on sustained weight reduction is observed in children and young adults with severe obesity. This underscores the need for additional evidence-based interventions for children and adolescents with severe obesity, including pharmacotherapy, before considering invasive procedures such as bariatric surgery. EVIDENCE ACQUISITION: This publication focuses on recent advances in pharmacotherapy of obesity with an emphasis on medications approved for common and rarer monogenic forms of pediatric obesity. EVIDENCE SYNTHESIS: We review medications currently available in the United States, both those approved for weight reduction in children and "off-label" medications that have a broad safety margin. CONCLUSION: It is intended that this review will provide guidance for practicing clinicians and will encourage future exploration for successful pharmacotherapy and other interventions for obesity in youth.
Authors: Vandana Raman, Anshu Gupta, Ambika P Ashraf, Emily Breidbart, Evgenia Gourgari, Manmohan Kamboj, Brenda Kohn, Sowmya Krishnan, Amit Lahoti, Kristal Matlock, Shilpa Mehta, Sejal Mistry, Ryan Miller, Laura Page, Danielle Reynolds, Joan C Han
Institutions: University of Utah, Virginia Commonwealth University, Children's Hospital of Richmond at VCU, University of Alabama at Birmingham, NYU Langone Health, New York University, Georgetown University, Nationwide Children's Hospital, The Ohio State University, University of Oklahoma Health Sciences Center, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Medical University of South Carolina, New York Medical College, University of Maryland, Baltimore, Duke University, Duke Medical Center, University of South Florida, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,400
OpenAlex ID: W4290068868